Answers are grounded in this paper and cite their sources.
Background MET exon 14 ( MET ex14) skipping alterations are a primary oncogenic driver mutation in a subset of non-small cell lung cancer (NSCLC) patients leading to poor prognosis. This post-marketing surveillance (jRCT2031200409) evaluated the safety and effectiveness of capmatinib, a MET receptor-targeted therapy, in real-world clinical practice among Japanese patients with unresectable advanced/recurrent NSCLC harboring MET ex14 skipping alterations. Methods This was a multicenter, non-interventional, post-marketing surveillance conducted across Japan. Data were collected for treatment exposure (duration and dose intensity), safety (adverse events, adverse drug reactions [ADRs], and serious ADRs), and effectiveness endpoints (including objective response rate [ORR], overall survival [OS], and progression-free survival [PFS]). Results We enrolled 109 patients. The median duration of capmatinib treatment was 98 days and the median dose was 759.06 mg/day. The overall incidences of ADRs of any grade and grade ≥3 were 75.49% and 25.49%, respectively. Serious ADRs occurred in 20 patients (19.61%). These included interstitial lung disease and renal impairment, both of which occurred in three (2.94%) patients. The ORR in the overall cohort was 30.49%, yielding a higher effectiveness in the first-line setting (50.00%) compared with later lines of therapy (27.40%). Both OS and PFS also showed more favorable trends with first-line treatment. Prior treatment history with kinase inhibitors was shown to have a possible association with ORR. Conclusions Capmatinib was generally well tolerated and effective in Japanese patients with NSCLC and MET ex14 skipping alterations in real-world clinical practice. The findings confirm the favorable safety profile of capmatinib with no new/unexpected safety signals. Clinical trial registration jRCT2031200409.
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (2026) studied this question.
Synapse has enriched 7 closely related papers on similar clinical questions. Consider them for comparative context: